Trial
NCT06520202
RHPRG4 FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Lubris Bio Pty Ltd
Collaborators
—
Condition
Sjogren's Syndrome With Dry Eye
Intervention
rhPRG4 (450 µg/mL)
Why stopped
Efficacy signal substantial enough to move to a larger sturdy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-09-29